Company Ramps Up Efforts to Target Inflammation to Combat Heart Disease

Assigning a 55.7% overall probability that company's upcoming data will be positive.

Inflammation can set off a chain reaction in the body, from triggering autoimmune flare-ups to damaging the walls of arteries. In fact, progressive inflammation in blood vessels often contributes to atherosclerotic cardiovascular disease (ASCVD), which can lead to serious events like heart attacks or strokes.

Researchers have long recognized that widely used treatments, such as statins, fall short of fully addressing the underlying inflammatory process in ASCVD. Recent efforts have zeroed in on blocking certain cytokines, particularly interleukin-1β (IL-1β) and interleukin-6 (IL-6), to prevent arterial hardening and dangerous clots. One developer, building on early success in this field, plans to share phase II results on its next-generation therapy for ASCVD in the second quarter of 2025.

We currently assign a 55.7% overall probability that these upcoming data will be positive.

MACE Scores are based on:

• Market Demand

• Adoption by payers and key opinion leaders (KOLs)

• Clinical progress

• Experience and capital.